bupropion and naltrexone

Weight loss drug decreases heart attacks? Contrave and early data


Members Only: 


fireworks A study of 4,500 patients using a new weight loss drug called Contrave (bupriprion and naltrexone) had the expected effect of a weight loss benefit, and the drug was FDA approved. A study of 8,910 people in a follow up study had the weight loss benefit, however; the patients taking Contrave had fewer heart attacks than the people who didn't take it.

There is controversy over this trial and apparent early leaks of data, but the information that patients taking the drug had fewer heart attacks is stunning. Importantly, the researchers doing the study thought the benefit on heart attacks may be a direct effect of the drug combination!

More to follow as always.

Where's the beef? FDA rejects Contrave combination of two FDA approved medicines

two women angry IN a suprise move, the FDA decided against the advice of its own expert panel and apparently has postponed approval of the new weight loss drug called Contrave. The shocking aspect of this action is that Contrave is a combination of two medicines WHICH ARE ALREADY APPROVED BY THE FDA.

Waiting for weight loss and Contrave

woman with blue face Are you getting blue in the face waiting for a new prescription weight loss drug? Today may be your day. The expert advisory committee of the FDA (Endocrine and Metabolic) recommended that the FDA approve Contrave.

Approval Date: 
Mon, 01/31/2011

Contrave and long wait for a new weight loss drug is probably over

food on plate The Endocrine and metabolic committee of the FDA recommended 13-7 to approve the first weight loss drug since 1999. Contrave (a combination of bupropion and naltrexone) was recommended for approval and while the FDA usually follows the vote of its expert committees, it is not bound to do so.

Contrave may join weight loss weapons in December

food on plate Weight loss medicines have not had such a good track record recently when being considered by the FDA. Yet another candidate is named Contrave and is a combination of two medicines (bupropion SR and naltrexone SR) in a single pill. The FDA expert advisory panel (Endocrine and Metabolic committee) will meet to consider this combination pill in December. 

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.